Lucid Diagnostics Analyst Ratings
Lucid Diagnostics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2023 | 87.92% | Needham | → $2.8 | Reiterates | Buy → Buy |
| 05/17/2023 | 168.46% | Cantor Fitzgerald | $4.5 → $4 | Maintains | Overweight |
| 05/17/2023 | 87.92% | Needham | $2.6 → $2.8 | Maintains | Buy |
| 04/21/2023 | 74.5% | Needham | → $2.6 | Reiterates | → Buy |
| 03/14/2023 | 74.5% | Needham | $3.1 → $2.6 | Maintains | Buy |
| 11/18/2022 | 134.9% | BTIG | $5 → $3.5 | Maintains | Buy |
| 11/15/2022 | 108.05% | Needham | $4.25 → $3.1 | Maintains | Buy |
| 08/16/2022 | 185.23% | Needham | $5 → $4.25 | Maintains | Buy |
| 05/12/2022 | 235.57% | Needham | $7 → $5 | Maintains | Buy |
| 03/29/2022 | 705.37% | Canaccord Genuity | $18 → $12 | Maintains | Buy |
| 03/29/2022 | 369.8% | Needham | $13 → $7 | Maintains | Buy |
| 12/27/2021 | 973.83% | Ascendiant Capital | → $16 | Initiates Coverage On | → Buy |
| 12/15/2021 | 772.48% | Needham | $17 → $13 | Maintains | Buy |
| 11/08/2021 | 839.6% | BTIG | → $14 | Initiates Coverage On | → Buy |
| 11/08/2021 | 1108.05% | Canaccord Genuity | → $18 | Initiates Coverage On | → Buy |
| 11/08/2021 | 1309.4% | Cantor Fitzgerald | → $21 | Initiates Coverage On | → Overweight |
| 11/08/2021 | 1040.94% | Needham | → $17 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/16/2023 | 87.92% | 尼德姆 | → 2.8 美元 | 重申 | 購買 → 購買 |
| 05/17/2023 | 168.46% | 坎託·菲茨傑拉德 | 4.5 美元 → 4 美元 | 維護 | 超重 |
| 05/17/2023 | 87.92% | 尼德姆 | 2.6 美元 → 2.8 美元 | 維護 | 購買 |
| 04/21/2023 | 74.5% | 尼德姆 | → 2.6 美元 | 重申 | → 購買 |
| 03/14/2023 | 74.5% | 尼德姆 | 3.1 美元 → 2.6 美元 | 維護 | 購買 |
| 11/18/2022 | 134.9% | BTIG | 5 美元 → 3.5 美元 | 維護 | 購買 |
| 11/15/2022 | 108.05% | 尼德姆 | 4.25 美元 → 3.1 美元 | 維護 | 購買 |
| 08/16/2022 | 185.23% | 尼德姆 | 5 美元 → 4.25 美元 | 維護 | 購買 |
| 2022 年 12 月 5 日 | 235.57% | 尼德姆 | 7 美元 → 5 美元 | 維護 | 購買 |
| 2022 年 3 月 29 日 | 705.37% | Canaccord Genu | 18 美元 → 12 美元 | 維護 | 購買 |
| 2022 年 3 月 29 日 | 369.8% | 尼德姆 | 13 美元 → 7 美元 | 維護 | 購買 |
| 2021 年 12 月 27 日 | 973.83% | 上升資本 | → 16 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 12 月 15 日 | 772.48% | 尼德姆 | 17 美元 → 13 美元 | 維護 | 購買 |
| 2021 年 8 月 11 日 | 839.6% | BTIG | → 14 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 8 月 11 日 | 1108.05% | Canaccord Genu | → 18 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 8 月 11 日 | 1309.4% | 坎託·菲茨傑拉德 | → 21 美元 | 啓動覆蓋開啓 | → 超重 |
| 2021 年 8 月 11 日 | 1040.94% | 尼德姆 | → 17 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Lucid Diagnostics (LUCD)?
Lucid Diagnostics（LUCD）的目標價格是多少？
The latest price target for Lucid Diagnostics (NASDAQ: LUCD) was reported by Needham on August 16, 2023. The analyst firm set a price target for $2.80 expecting LUCD to rise to within 12 months (a possible 87.92% upside). 7 analyst firms have reported ratings in the last year.
Needham於2023年8月16日公佈了Lucid Diagnostics（納斯達克股票代碼：LUCD）的最新目標股價。這家分析公司將目標股價定爲2.80美元，預計LUCD將在12個月內升至12個月內（可能上漲87.92％）。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Lucid Diagnostics (LUCD)?
分析師對Lucid Diagnostics（LUCD）的最新評級是多少？
The latest analyst rating for Lucid Diagnostics (NASDAQ: LUCD) was provided by Needham, and Lucid Diagnostics reiterated their buy rating.
Lucid Diagnostics（納斯達克股票代碼：LUCD）的最新分析師評級由Needham提供，Lucid Diagnostics重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Lucid Diagnostics (LUCD)?
Lucid Diagnostics（LUCD）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lucid Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lucid Diagnostics was filed on August 16, 2023 so you should expect the next rating to be made available sometime around August 16, 2024.
分析師在進行了廣泛的研究，包括瀏覽公開財務報表、與Lucid Diagnostics的高管和客戶交談以及聽取業績電話會議後得出股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Lucid Diagnostics 的最後評級是在2023年8月16日提交的，因此你應該預計下一個評級將在2024年8月16日左右公佈。
Is the Analyst Rating Lucid Diagnostics (LUCD) correct?
分析師評級 Lucid Diagnostics (LUCD) 正確嗎？
While ratings are subjective and will change, the latest Lucid Diagnostics (LUCD) rating was a reiterated with a price target of $0.00 to $2.80. The current price Lucid Diagnostics (LUCD) is trading at is $1.49, which is within the analyst's predicted range.
雖然評級是主觀的，會發生變化，但最新的Lucid Diagnostics（LUCD）評級得到了重申，目標股價爲0.00美元至2.80美元。Lucid Diagnostics（LUCD）目前的交易價格爲1.49美元，在分析師的預測區間內。